China Looks To Tighten Requirements On Adverse Event Reporting
This article was originally published in PharmAsia News
Executive Summary
Draft guidelines from SFDA would impact both foreign and domestic pharmaceutical manufacturers.
You may also be interested in...
China Overhauls ADR Reporting Regulations That Place Additional Responsibility On Drug Makers
SHANGHAI - China's State FDA released new guidelines for adverse drug reaction reporting May 24 that will dramatically increase the postmarket reporting responsibilities of manufacturers, distributors and hospitals
China Releases New Drug GMPs; Domestic Consolidation Expected To Accelerate
SHANGHAI - China's State FDA released its long-awaited good manufacturing practices guidelines for pharmaceutical products Feb. 12, which will begin to be implemented in all new drug manufacturing sites in March
Medtechs Must Reflect On China Localization Policies As VBP Expands
China continues to roll out volume-based procurement for medical devices and pharma products and companies should plan their strategies accordingly, advises EY Parthenon’s Hua Su.